BTK inhibitor monotherapy or in combination with other treatments have shown good clinical efficacy in newly diagnosed and R/R PCNSL and are well tolerated, but BTKi resistance remains an unavoidable problem. This evidence concerns the gene IBTK and primary central nervous system lymphoma.